3 completed, 2 unknown, 1 not yet recruiting, 1 recruiting. 8 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 3, Unknown 2, Not yet recruiting 1, Recruiting 1, Terminated 1 |
| Phase 1 | 1 | Terminated 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Long QT Syndrome: new trials by email Literature Review of Long QT Syndrome trials Research Report on Long QT Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of the Efficacy and Safety of THRV-1268 in Participants With Long QT Syndrome Type 2 (LQTS2) and Type 3 (LQTS3) baseline lead-in, THRV-1268 - Long QT Syndrome (LQTS) 2 | Phase 2 / Phase 3 | Recruiting | Thryv Therapeutics, Inc. | 84 | 2026-03-07 | 2026-09-21 |
| N-of-1 in ATS and MEPPC Flecainide, Flecainide + beta-blocker - Andersen Tawil Syndrome, Multifocal Ectopic Purkinje-related Premature Contractions | Phase 2 | Not yet recruiting | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 10 | 2025-03-01 | 2025-01-29 |
| Study of LQT-1213 on QTc-induced Prolongation in Healthy Adult Subjects (Part1) and on Congenital Long QT in Patients Diagnosed With Type 2 or 3 Long QT Syndrome (Part 2). LQT-1213, Placebo, Dofetilide 250 μg Cap - Long QT Syndrome | Phase 1 / Phase 2 | Terminated | Thryv Therapeutics, Inc. | 42 | 2023-03-12 | 2025-07-24 |
| Mutation-specific Therapy for the Long QT Syndrome Lumacaftor / Ivacaftor, Orkambi® Oral Tablet - Long QT Syndrome | Phase 2 | Completed | Istituto Auxologico Italiano | 16 | 2021-06-15 | 2025-04-25 |
| Long QT Syndrome Screening in Newborns QTScreen ECG Recorder - Long QT Syndrome | Phase 2 | Unknown | QT Medical, Inc. | 4000 | 2015-06-01 | 2016-09-28 |
| Influence of Progesterone Administration on Drug-Induced QT Interval Lengthening Progesterone, Placebo, Ibutilide - Prolonged QT Interval in EKG and Sudden Death | Phase 2 | Completed | Indiana University | 19 | 2013-04-01 | 2015-10-30 |
| Long Term Prophylactic Therapy of Congenital Long QT Syndrome Type III (LQT3) With Ranolazine Ranolazine - Long QT Syndrome Type 3 | Phase 2 | Unknown | Tel-Aviv Sourasky Medical Center | 10 | 2012-10-01 | 2015-03-26 |
| Long-term Efficacy Study of Sodium Channel Blocker in LQT3 Patients Placebo, Ranolazine - Long QT Syndrome | Phase 2 | Completed | University of Rochester | 25 | 2012-09-01 | 2022-04-07 |
Andersen Syndrome (1) · Channelopathies (1) · Death, Sudden, Cardiac (1) · Jervell-Lange Nielsen Syndrome (1) · Long QT syndrome type 3 (1) · Risk Reduction Behavior (1) · Torsades de Pointes (1)
Arrhythmias, Cardiac (8) · Cardiac Conduction System Disease (8) · Cardiovascular Abnormalities (8) · Cardiovascular Diseases (8) · Congenital Abnormalities (8) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (8) · Heart Defects, Congenital (8) · Heart Diseases (8) · Pathologic Processes (8) · Pathological Conditions, Signs and Symptoms (8) · Behavior (1) · Death (1) · Death, Sudden (1) · Heart Arrest (1)
Ranolazine (2) · Adrenergic beta-Antagonists (1) · Capsules (1) · Flecainide (1) · Progesterone (1) · dofetilide (1) · ibutilide (1) · ivacaftor (1) · lumacaftor (1) · lumacaftor, ivacaftor drug combination (1)
Thryv Therapeutics, Inc. (2) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1) · Indiana University (1) · Istituto Auxologico Italiano (1) · QT Medical, Inc. (1) · Tel-Aviv Sourasky Medical Center (1) · University of Rochester (1)
United States (5) · Israel (1) · Italy (1)
James E Tisdale, BSc, PharmD (1) · Jan Matousek, DO (1) · Lia Crotti, MD (1) · Peter J Schwartz, MD (1) · Ruey-Kang Chang, M.D., M.P.H. (1) · Wojciech Zareba, MD,PhD (1)